KELLY GLAS: Open Payments
NPI 1790410033 · LA MESA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$686 in 33 payments from 13 companies in 2025. Trend: 2023 $428 · 2024 $1,284 · 2025 $686
Food & beverage: $641Education: $45
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 12 | $156 |
| AstraZeneca Pharmaceuticals LP | 4 | $141 |
| Lilly USA, LLC | 2 | $63 |
| Novo Nordisk Inc | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Lundbeck LLC | 2 | $45 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $25 |
| IRONWOOD PHARMACEUTICALS, INC | 1 | $24 |
| SHIELD THERAPEUTICS INC | 1 | $24 |
Products named: FARXIGA, REXULTI, EVENITY, OTEZLA, Kerendia, Linzess, ACCRUFER, Wegovy.
Industry payments across CA — which companies pay providers there.
